Physician profile
David Stockwell
NPI 1326080490
$2,309.56
in general payments reported to CMS, 2019-2025
28 companies · $62.16 in 2025
The $62.16 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $224 · 2021: $240 · 2022: $256 · 2023: $501 · 2024: $369 · 2025: $62.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $822.82 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $297.03 | 2019-2022 | |
| Medtronic, INC. | $135.21 | 2021 | |
| Celgene Corporation | $134.06 | 2021-2024 | Zeposia |
| Pfizer INC. | $109.58 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.51 | 2019-2025 | Eohilia |
| Daiichi Sankyo INC. | $96.13 | 2019-2021 | |
| Janssen Biotech, INC. | $93.48 | 2019-2023 | Stelara, Simponi, Simponi Aria |
| Gilead Sciences, INC. | $63.08 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $57.19 | 2022-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $39.12 | 2019 | |
| Ironwood Pharmaceuticals, INC | $38.27 | 2019-2023 | Linzess |
| Ardelyx, INC. | $32.70 | 2023 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $32.67 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $32.32 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.28 | 2023 | Cyltezo |
| Ucb, INC. | $25.53 | 2019 | |
| Amgen INC. | $20.51 | 2019 | |
| Shire North American Group INC | $19.57 | 2019 | |
| Lilly USA, LLC | $17.83 | 2024 | Omvoh |
| Endo Pharmaceuticals INC. | $17.05 | 2019 | |
| Covidien LP | $15.68 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.60 | 2022 | |
| Intra-Sana Laboratories | $14.82 | 2022 | |
| Alfasigma USA, INC. | $14.64 | 2020 | |
| W. L. Gore & Associates, INC. | $12.70 | 2022 | |
| Amag Pharmaceuticals, INC. | $12.62 | 2019 | |
| Allergan, INC. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stockwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.